Udoma & Belo-Osagie’s M&A team has advised Micro Labs Limited India (Micro Labs) on its acquisition of Servier International B.V. and Servier Nederland B.V.’s controlling equity stake in Swiss Pharma Nigeria Limited (SwiPha).
Micro Labs, a fully integrated pharmaceutical company, manufactures and markets branded generic formulations globally, with a strong presence in over 50 countries. Specialising in cardiology, diabetology, pain management, dermatology, ophthalmology, and neurology, it serves India and emerging markets. SwiPha produces and distributes affordable, high-quality branded generics across diverse therapeutic areas.
This acquisition is expected to boost supply chain efficiency, enhance manufacturing, improve access to affordable medicines across Nigeria and Africa (focusing on malaria, infections, cardio-metabolic diseases, and more), and expand treatment options. SwiPha’s WHO-approved plant will strengthen Micro Labs’ regional manufacturing, export capabilities, and distribution networks.
The UUBO team was led by M&A and Private Equity & Venture Capital teams partner, Folake Elias-Adebowale, and team members including Tobechi Nwokocha, Etido David, Elo Adhekpukoli, Aanu Odunaike, Precious David, Dumebi Anike-Nweze, and Ayomide Soretire.
Learn more: https://pharmanewsonline.com/micro-labs-acquires-swipha-expands-footprint-in-nigeria-africa/
For more information about UUBO’s M&A, Private Equity and 21 other practice group offerings, please visit www.uubo.org.
